Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Improvement in CT 69% Improvement Relative Risk Viral clearance 71% Favipiravir for COVID-19  Cai et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 80 patients in China Lower pneumonia (p=0.042) and improved viral clearance (p=0.025) c19early.org Cai et al., Engineering, March 2020 Favors favipiravir Favors control

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007
Mar 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.
risk of no improvement in CT, 68.7% lower, OR 0.31, p = 0.04, treatment 35, control 45, inverted to make OR<1 favor treatment, multivariate, RR approximated with OR.
risk of no viral clearance, 70.9% lower, HR 0.29, p = 0.03, treatment 35, control 45, inverted to make HR<1 favor treatment, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cai et al., 18 Mar 2020, retrospective, China, peer-reviewed, 26 authors.
This PaperFavipiravirAll
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai, Minghui Yang, Dongjing Liu, Jun Chen, Dan Shu, Junxia Xia, Xuejiao Liao, Yuanbo Gu, Qiue Cai, Yang Yang, Chenguang Shen, Xiaohe Li, Ling Peng, Deliang Huang, Jing Zhang, Shurong Zhang, Fuxiang Wang, Jiaye Liu, Li Chen, Shuyan Chen, Zhaoqin Wang, Zheng Zhang, Ruiyuan Cao, Wu Zhong, Yingxia Liu, Lei Liu
Engineering, doi:10.1016/j.eng.2020.03.007
There is currently an outbreak of respiratory disease caused by a novel coronavirus. The virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes has been named coronavirus disease 2019 . More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was 1%-2%. No specific treatment has been reported. Herein, we examined the effects of favipiravir (FPV) versus lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily) plus interferon (IFN)-a by aerosol inhalation (5 million international unit (IU) twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1-14: 400 mg/100 mg twice daily) plus IFN-a by aerosol inhalation (5 million IU twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance median time was found for the FPV arm versus the control arm (4 d (interquartile range (IQR): 2.5-9) versus 11 d (IQR: 8-13), P < 0.001). The FPV arm also showed significant improvement in chest CT compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest CT. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse events were found in the FPV arm than in the control arm. In this open-label before-after controlled study, FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection.
References
Authors' Contribution Lei, Liu, Liu, Cai, Yang et al., that they have no conflict of interest or financial conflicts to disclose
Bouazza, Treluyer, Foissac, Mentré, Taburet et al., Favipiravir for children with Ebola, Lancet
Chafekar, Fielding, MERS-CoV: understanding the latest human coronavirus threat, Viruses
Chang, Yu, Chang, Galvin, Liu et al., Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT, Radiology
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res
Grieser, Goldmann, Steffen, Kastrup, Fernández et al., Computed tomography findings from patients with ARDS due to Influenza A (H1N1) virus-associated pneumonia, Eur J Radiol
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Li, Guan, Wu, Wang, Zhou et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Madelain, Oestereich, Graw, Nguyen, De Lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Mdvi, Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults [Internet
Oestereich, Lüdtke, Wurr, Rieger, Muñoz-Fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Sissoko, Laouenan, Folkesson, Lebing, Beavogui et al., Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit